Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients

Next Previous
Search
Trial Profile

Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax) and Trastuzumab in High-risk HER2+ Breast Cancer Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nelipepimut-S (Primary) ; Sargramostim (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Dec 2022 Results presented at the 45th Annual San Antonio Breast Cancer Symposium
    • 28 Feb 2022 Status changed from active, no longer recruiting to completed.
    • 13 May 2021 According to a Sellas Life Sciences Group media release, the data safety monitoring board recommended that, given the small size of the study and in order to preserve the statistical power of the study, the primary analysis of the study be completed upon the completion of three years of follow-up on every patient or until more events are collected. The company expects the primary analysis in this study to be completed by the end of 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top